What Arkuda Therapeutics does

Arkuda Therapeutics is a privately held biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts, that develops small-molecule therapeutics targeting progranulin biology and lysosomal dysfunction for neurodegenerative diseases. The company's lead program is a progranulin enhancer designed to address progranulin deficiencies underlying GRN-related frontotemporal dementia (FTD), with stated pipeline potential in Alzheimer's disease and Parkinson's disease. The underlying scientific premise is that restoring progranulin levels can correct lysosomal and microglial dysfunction that drives neuronal degeneration, and Arkuda is positioning itself as a domain specialist in this biology rather than a broad neurodegeneration player.

The company was co-founded by Gerhard Koenig (founder & CEO) and Duane Burnett (co-founder & CTO). It is venture-backed, having raised approximately $108 million in aggregate funding across a $44 million Series A (led by Atlas Venture and Pfizer Venture Investments, November 2019), a Michael J. Fox Foundation grant (December 2021), and a $64 million Series B (led by Cormorant Asset Management and Pivotal bioVenture Partners, February 2022). The investor base spans top-tier biotech VCs (Atlas Venture, Mission BioCapital, Cormorant, Pivotal, Tekla Capital Management, Surveyor Capital) and strategic pharma capital (Pfizer Venture Investments, Eli Lilly), giving the company both financial runway and potential downstream partnership optionality. The Series B capital is earmarked for IND-enabling studies on the lead program and for pipeline expansion targeting lysosomal dysfunction.

Arkuda's business model is that of a pre-clinical biotech: value creation is driven by advancing pipeline assets through preclinical and clinical milestones toward eventual out-licensing, partnership, or acquisition. There are no commercial products, no revenue, no pricing model, and no disclosed go-to-market motion in the input data. The ultimate end-users of any approved therapy would be patients with neurodegenerative diseases, with GRN-related FTD as the primary initial indication; given the early stage, customer concentration in the conventional commercial sense is not yet applicable. The company's headcount band of 11–50 employees and its Series B timing suggest an active but measured growth profile rather than hyper-expansion.

Name

Arkuda Therapeutics

Website

https://arkudatx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Arkuda Therapeutics is a privately held Cambridge, MA-based biopharmaceutical company developing progranulin-enhancing small molecules for neurodegenerative diseases, with a lead program targeting GRN-related frontotemporal dementia and pipeline potential in Alzheimer's and Parkinson's.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

Keywords

• Neurodegenerative disease therapeutics
• Progranulin enhancement
• Frontotemporal dementia treatments
• Lysosomal biology research
• Biopharmaceutical drug discovery

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

Arkuda Therapeutics is a biopharmaceutical company developing a progranulin enhancer program aimed at treating neurodegenerative diseases caused by progranulin deficiencies. Its lead program is advancing through IND-enabling studies with an initial clinical focus on GRN-related frontotemporal dementia, with potential expansion to Alzheimer's disease and Parkinson's disease populations.

Product overview

Arkuda Therapeutics is a biopharmaceutical company developing treatments for neurodegenerative diseases. The company is focused on progranulin enhancement therapies targeting lysosomal dysfunction. Their lead progranulin enhancer program is in IND-enabling studies, with an initial clinical focus on GRN-related frontotemporal dementia. The pipeline also explores potential applications in Alzheimer's and Parkinson's diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• Progranulin Enhancer Program

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Alector: Alector is a clinical-stage biotechnology company developing immuno-neurology treatments for neurodegeneration, most notably targeting progranulin in FTD and Alzheimer's. Arkuda's progranulin enhancer program targets the same biology, making Alector the most direct mechanistic and indication-level peer.
• Denali Therapeutics: Denali Therapeutics develops therapies for neurodegeneration with a strong focus on lysosomal biology, enzyme replacement, and microglia-modulating mechanisms. Its lysosomal dysfunction pipeline closely parallels Arkuda's lead scientific approach.
• Prevail Therapeutics: Prevail Therapeutics developed gene therapies for neurodegenerative diseases including GRN-related FTD, and was acquired by Eli Lilly in 2021. It is one of the closest competitors to Arkuda in FTD and progranulin biology.
• Passage Bio: Passage Bio is a clinical-stage genetic medicines company developing AAV-delivered therapies for CNS diseases, with FTD-GRN as a flagship program. Directly comparable to Arkuda on indication, modality (gene-based delivery), and patient population.
• Praxis Precision Medicines: Praxis Precision Medicines focuses on genetic and rare neurological disorders, including movement disorders and dementias. It shares Arkuda's rare-neuro positioning and small-cap clinical-stage profile.
• Wave Life Sciences: Wave Life Sciences develops stereopure antisense oligonucleotides for genetic neurological and neuromuscular disorders including FTD and Huntington's. Comparable on modality (oligonucleotide/RNA-based) and rare-CNS target population.

Emerging players

• Lexeo Therapeutics: Lexeo Therapeutics is an early-stage genetic medicines company with CNS programs including FTD. It overlaps with Arkuda on rare-neurodegenerative target populations and gene-/modulator-based approaches.
• Vigil Neuroscience: Vigil Neuroscience develops TREM2-activating therapies for rare and common neurodegenerative diseases with microglial involvement. Strongly overlaps with Arkuda's emphasis on microglial and lysosomal biology in neurodegeneration.

Broad incumbents

• Alnylam Pharmaceuticals: Alnylam is a commercial-stage RNAi therapeutics company with rare neurological and lysosomal-storage programs in its pipeline. Comparable on genetic-medicines approach and rare-disease focus, though broader and more mature than Arkuda.
• Ionis Pharmaceuticals: Ionis is a leading antisense oligonucleotide company with established rare-neurology franchises (e.g., SMA, ALS) and CNS pipeline. Comparable on rare-CNS genetic-medicines positioning but operates at a much larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ArkudaTx

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arkuda Therapeutics